Premises and Purpose of the study: Cardio-oncology focuses on the need for close collaboration between oncologists and cardiologists in order to prevent and promptly detect and treat cardiovascular toxicities related to oncological treatment (CTR-CVT) in the era of new drugs. Materials and Methods: Since June 2023 has been organized a specific cardiological ambulatory for our oncological patients candidates to potentially cardiotoxic agents. In according to ESC 2022 guidelines, all patients were screened for cardiovascular risk, past and programmed therapy, HBA1c, lypidic profile, cardiac troponin and BNP determination, pressure, ECG and echocardiogram with global longitudinal strain measurement. A referring oncologist, hematologist and cardiology team has been identified to discuss face-face complex cases and implement competence and process. Results: After the first six months overall 74 pts were evaluated including 29 GI, 19 breast, 10 lung, 4 GU, 6 lymphoma, 3 chronic lymphocytic leukemia and 3 other cancers. Based on HFA-ICOS score, 37 pts were classified as high risk, 14 moderate and 23 low risk.10 pts required further cardiological assessments, but only in 1 patient was necessary to change the proposed oncological therapy. In more than 90% pts, primary prevention or cardioprotective strategy was proposed. During this time, no patient developed CTR-CVT. Conclusions: Follow-up for long- term outcomes is ongoing. In our experience, cardio-oncology service is feasible even in non-hub hospital and is a model for patient centered care.
A Mon, study studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: